The mission of MoGlyNet is to define a joint doctorate educational training model in Drug Discovery and Development where Academia and Industry join their forces for: – creating a common platform of knowledge and language for early stage researchers (ESR) working in the Drug Discovery and Development area aiming to convey complementary pharma-skills – exploiting this platform to train a new generation of cutting-edge researchers and professionals highly attractive for employment by the European Pharma-industry – establishing structures for long-term cooperation, strengthening the relationships among the leading Universities and Pharma-enterprises and to continuously develop the research training platform that European industry relies on. To achieve the above objectives the main tasks of MoGlyNet are: – to train 12 ESRs in joint academic/industrial program of cutting-edge training-by-research, high quality supervision, complementary and transferable Pharma-skills training, inter-network secondments, and workshops/Summer Schools – to pursue an innovative research project that tackle a timely and important scientific problem with a multidisciplinary approach (from molecular modelling to in vivo studies). Atherosclerosis is an aging-related disease and our research approach for a better therapy of atherosclerosis will be focused on an enzymatic target, a key player in glycolysis/oxidative stress and therefore in pathological angiogenesis – to build a solid foundation for long-term European excellence in this field by disseminating MoGlyNet research/training outcomes and best practice into the partners Doctoral Schools, and by fostering long-term partnerships and collaborations that will outlast the Consortium – to transfer expertise/know-how among the Consortium participants and to external groups via networking activities, intersectorial exposure, secondments, workshops, sharing of learning material, public engagement and outreach activities.

MOGLYNET – Modulation of glycolytic flux as a new approach for treatment of atherosclerosis and plaque stabilization: a multidisciplinary study – H2020 / A. Corsini, A. Contini, G. De Meyer, M.L. Gelmi, M. Carini, M. Cascante, M. Zanda, P. Quax, S. Bellosta, W. Martinet. - In: IMPACT. - ISSN 2398-7073. - 2017:8(2017 Oct), pp. 26-28. [10.21820/23987073.2017.8.26]

MOGLYNET – Modulation of glycolytic flux as a new approach for treatment of atherosclerosis and plaque stabilization: a multidisciplinary study – H2020

A. Corsini
Primo
;
A. Contini
Secondo
;
M.L. Gelmi;M. Carini;S. Bellosta
Penultimo
;
2017

Abstract

The mission of MoGlyNet is to define a joint doctorate educational training model in Drug Discovery and Development where Academia and Industry join their forces for: – creating a common platform of knowledge and language for early stage researchers (ESR) working in the Drug Discovery and Development area aiming to convey complementary pharma-skills – exploiting this platform to train a new generation of cutting-edge researchers and professionals highly attractive for employment by the European Pharma-industry – establishing structures for long-term cooperation, strengthening the relationships among the leading Universities and Pharma-enterprises and to continuously develop the research training platform that European industry relies on. To achieve the above objectives the main tasks of MoGlyNet are: – to train 12 ESRs in joint academic/industrial program of cutting-edge training-by-research, high quality supervision, complementary and transferable Pharma-skills training, inter-network secondments, and workshops/Summer Schools – to pursue an innovative research project that tackle a timely and important scientific problem with a multidisciplinary approach (from molecular modelling to in vivo studies). Atherosclerosis is an aging-related disease and our research approach for a better therapy of atherosclerosis will be focused on an enzymatic target, a key player in glycolysis/oxidative stress and therefore in pathological angiogenesis – to build a solid foundation for long-term European excellence in this field by disseminating MoGlyNet research/training outcomes and best practice into the partners Doctoral Schools, and by fostering long-term partnerships and collaborations that will outlast the Consortium – to transfer expertise/know-how among the Consortium participants and to external groups via networking activities, intersectorial exposure, secondments, workshops, sharing of learning material, public engagement and outreach activities.
English
Settore BIO/14 - Farmacologia
Articolo
Esperti anonimi
Ricerca di base
Pubblicazione scientifica
ott-2017
Science Impact
2017
8
26
28
3
Pubblicato
Periodico con rilevanza internazionale
crossref
Aderisco
info:eu-repo/semantics/article
MOGLYNET – Modulation of glycolytic flux as a new approach for treatment of atherosclerosis and plaque stabilization: a multidisciplinary study – H2020 / A. Corsini, A. Contini, G. De Meyer, M.L. Gelmi, M. Carini, M. Cascante, M. Zanda, P. Quax, S. Bellosta, W. Martinet. - In: IMPACT. - ISSN 2398-7073. - 2017:8(2017 Oct), pp. 26-28. [10.21820/23987073.2017.8.26]
reserved
Prodotti della ricerca::01 - Articolo su periodico
10
262
Article (author)
no
A. Corsini, A. Contini, G. De Meyer, M.L. Gelmi, M. Carini, M. Cascante, M. Zanda, P. Quax, S. Bellosta, W. Martinet
File in questo prodotto:
File Dimensione Formato  
art00010.pdf

accesso riservato

Tipologia: Publisher's version/PDF
Dimensione 304.56 kB
Formato Adobe PDF
304.56 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/630975
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact